<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31591201</article-id>
<article-id pub-id-type="pmc">6815178</article-id>
<article-id pub-id-type="publisher-id">201906817</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1906817116</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Immunology and Inflammation</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tsilioni</surname>
<given-names>Irene</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patel</surname>
<given-names>Arti B.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pantazopoulos</surname>
<given-names>Harry</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berretta</surname>
<given-names>Sabina</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conti</surname>
<given-names>Pio</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-2875-1394</contrib-id>
<name>
<surname>Leeman</surname>
<given-names>Susan E.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Theoharides</surname>
<given-names>Theoharis C.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, <institution>Tufts University School of Medicine</institution>, Boston, <addr-line>MA</addr-line> 02111;</aff>
<aff id="aff2"><sup>b</sup>Sackler School of Graduate Biomedical Sciences, <institution>Tufts University School of Medicine</institution>, Boston, <addr-line>MA</addr-line> 02111;</aff>
<aff id="aff3"><sup>c</sup>Translational Neuroscience Laboratory, <institution>McLean Hospital, Harvard Medical School</institution>, Belmont, <addr-line>MA</addr-line> 02478;</aff>
<aff id="aff4"><sup>d</sup>Immunology Division, Postgraduate Medical School, <institution>University of Chieti</institution>, 65100 Pescara, <country>Italy</country>;</aff>
<aff id="aff5"><sup>e</sup>Department of Pharmacology, <institution>Boston University School of Medicine</institution>, Boston, <addr-line>MA</addr-line> 02118;</aff>
<aff id="aff6"><sup>f</sup>Department of Internal Medicine, <institution>Tufts Medical Center, Tufts University School of Medicine</institution>, Boston, <addr-line>MA</addr-line> 02111</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>2</sup>To whom correspondence may be addressed. Email: <email>sleeman@bu.edu</email> or <email>theoharis.theoharides@tufts.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by Susan E. Leeman, July 15, 2019 (sent for review May 3, 2019; reviewed by Charles A. Dinarello and Richard E. Frye)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: I.T., P.C., and T.C.T. designed research; I.T., A.B.P., and H.P. performed research; S.B. contributed new reagents/analytic tools; I.T. analyzed data; I.T., S.E.L., and T.C.T. wrote the paper; A.B.P. and H.P. prepared the brain mRNA; S.B. advised on selection of brain sections; P.C. advised on the importance of IL-37; and S.E.L. discussed the results and corrected the manuscript.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: C.A.D., University of Colorado Denver; and R.E.F., Alberta Children’s Hospital Research Institute.</p>
</fn>
<fn fn-type="present-address" id="fn1">
<p><sup>1</sup>Present address: Department of Neurobiology and Anatomical Sciences, University of Mississippi Medical Center, Jackson, MS 39216.</p>
</fn>
<fn fn-type="COI-statement">
<p>Competing interest statement: T.C.T. is the inventor of US patents no. 7,906,153; no. 8,268,365, and no. 9,050,275 for the treatment of autism and neuroinflammatory conditions.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>22</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>7</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>116</volume>
<issue>43</issue>
<fpage>21659</fpage>
<lpage>21665</lpage>
<permissions>
<copyright-year>2019</copyright-year>
<license>
<ali:license_ref specific-use="vor" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://www.pnas.org/site/aboutpnas/licenses.xhtml</ali:license_ref>
<license-p>Published under the <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/site/aboutpnas/licenses.xhtml">PNAS license</ext-link>.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201906817.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>IL-37, an antiinflammatory cytokine, is increased along with the proinflammatory cytokine IL-18 and its receptor IL-18R in the amygdala and dorsolateral prefrontal cortex of children with autism spectrum disorder (ASD). IL-37 inhibits neurotensin (NT)-stimulated secretion and gene expression of IL-1β and CXCL8 from cultured human microglia, the resident immune cells of the brain. Moreover, NT, IL-1β, and TNF increase gene expression of IL-37 in these microglia. These findings highlight the important role of NT in the activation of microglia and of IL-37 in the inhibition of inflammation, thus supporting the development of IL-37 as a treatment for ASD.</p>
</abstract>
<abstract>
<p>Autism spectrum disorder (ASD) does not have a distinct pathogenesis or effective treatment. Increasing evidence supports the presence of immune dysfunction and inflammation in the brains of children with ASD. In this report, we present data that gene expression of the antiinflammatory cytokine IL-37, as well as of the proinflammatory cytokines IL-18 and TNF, is increased in the amygdala and dorsolateral prefrontal cortex of children with ASD as compared to non-ASD controls. Gene expression of IL-18R, which is a receptor for both IL-18 and IL-37, is also increased in the same brain areas of children with ASD. Interestingly, gene expression of the NTR3/sortilin receptor is reduced in the amygdala and dorsolateral prefrontal cortex. Pretreatment of cultured human microglia from normal adult brains with human recombinant IL-37 (1 to 100 ng/mL) inhibits neurotensin (NT)-stimulated secretion and gene expression of IL-1β and CXCL8. Another key finding is that NT, as well as the proinflammatory cytokines IL-1β and TNF increase IL-37 gene expression in cultured human microglia. The data presented here highlight the connection between inflammation and ASD, supporting the development of IL-37 as a potential therapeutic agent of ASD.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorder</kwd>
<kwd>brain</kwd>
<kwd>inflammation</kwd>
<kwd>IL-37</kwd>
<kwd>neurotensin</kwd>
</kwd-group>
<counts>
<page-count count="7"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>